Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:disease
|
| gptkbp:associated_with |
deafness
pancreatitis myocarditis aseptic meningitis increased risk of complications in adults parotitis |
| gptkbp:caused_by |
gptkb:mumps_virus
|
| gptkbp:community_health |
vaccination campaigns
|
| gptkbp:complication |
gptkb:multiple_sclerosis
meningitis orchitis oophoritis |
| gptkbp:contagious_period |
2 days before to 5 days after swelling
|
| gptkbp:diagnosis |
clinical evaluation
serological testing |
| gptkbp:diseases |
gptkb:paramyxovirus
boosting vaccination rates documented in various countries still occur in unvaccinated populations |
| gptkbp:epidemiology |
seasonal peaks in late winter and spring
|
| gptkbp:first_vaccine_developed |
gptkb:1967
|
| gptkbp:global_incidence |
declined due to vaccination
|
| gptkbp:historical_significance |
major cause of childhood illness before vaccine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mumps
|
| gptkbp:incubation_period |
16 to 18 days
|
| gptkbp:infectious_agent |
single-stranded RNA virus
|
| gptkbp:is_common_in |
gptkb:children
adults |
| gptkbp:is_monitored_by |
ongoing in many countries
|
| gptkbp:is_recognized_as |
1772
|
| gptkbp:is_vulnerable_to |
gptkb:MMR_vaccine
second dose at 4-6 years first dose at 12-15 months approximately 88% after two doses |
| gptkbp:notable_figures |
Edward Jenner (vaccine pioneer)
|
| gptkbp:prevention |
vaccination
|
| gptkbp:public_awareness |
important for prevention
|
| gptkbp:risk_factor |
college students
young children unvaccinated individuals |
| gptkbp:scientific_classification |
recognizes mumps as a vaccine-preventable disease
|
| gptkbp:symptoms |
fatigue
headache muscle pain fever 7 to 10 days swollen salivary glands |
| gptkbp:transmission |
airborne droplets
|
| gptkbp:treatment |
supportive care
|
| gptkbp:treatment_focus |
relief of symptoms
|
| gptkbp:bfsParent |
gptkb:Hatfield_and_the_North
|
| gptkbp:bfsLayer |
6
|